Is BCRX a good stock to buy? We came across a bullish thesis on BioCryst Pharmaceuticals, Inc. on TradersPro’s Substack. In this article, we will summarize the bulls’ thesis on BCRX. BioCryst Pharmaceuticals, Inc.’s share was trading at $9.30 as of March 16th. BCRX’s trailing and forward P/E were 7.69 and 109.89 respectively according to Yahoo Finance.
Copyright: zneb076 / 123RF Stock Photo
BioCryst Pharmaceuticals, Inc. (BCRX) is a biotechnology company focused on developing and commercializing oral therapies for rare diseases, with its lead product targeting hereditary angioedema. This oral therapy provides patients a convenient alternative to injectable treatments, driving adoption through consistent symptom control and patient preference for ease of use.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
Revenue growth is further supported by expanding global distribution and increasing physician awareness, while the company’s pipeline of additional candidates targeting complement-mediated and other rare disorders offers potential long-term catalysts beyond its current commercial asset. Operating in the rare disease biotech niche, BioCryst benefits from strong pricing power, regulatory incentives, and active patient advocacy, with healthcare spending showing resilience even during broader economic uncertainty.
Specialty pharmaceuticals like BCRX tend to be less sensitive to traditional economic cycles, further supporting the investment case. Investor sentiment toward biotech has strengthened as capital markets stabilize and companies demonstrate clearer commercial traction, creating favorable conditions for share performance. Technical signals also indicate renewed momentum, with recent price action forming a confirmation bar on increasing volume, pushing the stock into a momentum zone where demand often accelerates as supply tightens and participation broadens. Given the sector’s sensitivity to clinical updates and regulatory developments, disciplined risk management is recommended.
Trailing stops, anchored to Fibonacci retracement levels and adjusted with new highs, allow investors to protect gains while participating in potential upside. Overall, BioCryst represents a compelling opportunity in rare disease biotechnology, combining a growing commercial franchise, an expanding pipeline, supportive market dynamics, and technical momentum, offering both near-term growth from its hereditary angioedema therapy and longer-term upside through future pipeline developments.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted its CRISPR platform, Casgevy’s commercial potential, partnership with Vertex, and a strong pipeline. CRSP’s stock price has appreciated by approximately 18.18% since our coverage. TradersPro shares a similar view but emphasizes BioCryst Pharmaceuticals, Inc. BCRX and its oral therapies, rare disease adoption, global reach, and regulatory incentives.
BioCryst Pharmaceuticals, Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 53 hedge fund portfolios held BCRX at the end of the fourth quarter which was 47 in the previous quarter. While we acknowledge the risk and potential of BCRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BCRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
